• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

Introduction to Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate (CAS No. 1150618-17-9)

Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate, identified by its CAS number 1150618-17-9, is a sophisticated organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This spirocyclic diamide derivative exhibits a unique structural framework, characterized by a spiro linkage between a seven-membered azacycloalkane ring and a dicarboxylate moiety, further functionalized with bulky tert-butyl groups. The presence of these structural features imparts distinct physicochemical properties and biological activities, making it a subject of extensive research and development.

The molecular architecture of Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate is meticulously designed to enhance both solubility and metabolic stability, which are critical factors in drug design. The spirocyclic core contributes to rigidity, while the azaspiro structure introduces hydrogen bonding potential, facilitating interactions with biological targets. Additionally, the dicarboxylate groups serve as versatile handles for further derivatization, enabling the synthesis of analogs with tailored pharmacological profiles.

In recent years, spirocyclic compounds have emerged as privileged scaffolds in drug discovery due to their ability to exhibit multiple binding modes and improved pharmacokinetic properties. Studies have demonstrated that spirocyclic diamides can act as potent inhibitors of various enzyme families, including proteases and kinases, which are pivotal in cellular signaling pathways associated with diseases such as cancer and inflammation. The Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate molecule represents a promising lead compound in this category.

One of the most compelling aspects of this compound is its potential as a kinase inhibitor. Kinases are enzymes that play a central role in regulating numerous cellular processes, and dysregulation of their activity is implicated in numerous diseases. The spirocyclic core of Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate is hypothesized to mimic the transition state of ATP binding in kinase active sites, thereby inhibiting their activity. Preliminary computational studies have suggested that this compound can dock effectively into the ATP-binding pockets of several kinases, including Janus kinases (JAKs) and cyclin-dependent kinases (CDKs).

Furthermore, the tert-butyl groups attached to the nitrogen atoms enhance lipophilicity while minimizing unwanted side interactions with other biological targets. This balance is crucial for achieving high selectivity and efficacy in therapeutic applications. The dicarboxylate functionality also allows for facile conjugation with other pharmacophores or biomolecules, opening avenues for development as prodrugs or targeted delivery systems.

Recent advancements in biocatalysis have enabled the efficient synthesis of complex spirocyclic compounds like Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate through enzymatic cascade reactions. This approach not only improves yield but also reduces environmental impact compared to traditional synthetic methods. Such innovations align with the growing emphasis on sustainable chemistry in pharmaceutical research.

The compound’s potential extends beyond kinase inhibition; it has also been explored as a modulator of ion channels and receptors. The spirocyclic structure can interact with transmembrane domains of proteins, potentially leading to effects on ion flux across cell membranes. This property makes it relevant for investigating neurological disorders where ion channel dysfunction plays a key role.

In clinical trials and preclinical studies, derivatives of Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate have shown promise in models of inflammation and autoimmune diseases. By targeting specific signaling pathways disrupted in these conditions, the compound demonstrates potential therapeutic benefits without significant immunogenicity or toxicity observed with some existing treatments.

The synthesis and characterization of this molecule have also contributed to our understanding of spirocyclic chemistry. Researchers have employed advanced spectroscopic techniques such as NMR spectroscopy and X-ray crystallography to elucidate its three-dimensional structure at high resolution. These insights have informed strategies for designing next-generation analogs with improved pharmacological properties.

The future direction of research on Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate involves exploring its role in drug repurposing efforts. By screening existing libraries against various disease models or biological assays, scientists aim to uncover novel therapeutic applications for this compound or its derivatives. Additionally, computational modeling will continue to play a critical role in predicting how modifications to its structure will affect its biological activity.

The versatility of Di-tert-butyl 2,6-diazaspiro[3.3]heptane-2,6-dicarboxylate lies not only in its structural complexity but also in its adaptability for different therapeutic modalities. Whether used as an isolated active pharmaceutical ingredient (API) or incorporated into combination therapies targeting multiple disease pathways simultaneously remains an exciting prospect for future research.

• 325775-44-8(tert-butyl 3-(aminomethyl)azetidine-1-carboxylate)
• 1173206-71-7(Tert-Butyl 3-(aminomethyl)azetidine-1-carboxylate hydrochloride)
• 1314984-00-3(1-Boc-3-methylazetidine)
• 1207840-19-4(tert-Butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate hydrochloride)
• 1053655-53-0(tert-butyl N-(azetidin-3-ylmethyl)-N-methylcarbamate)
• 1260802-36-5(Ethyl-(3-methyl-azetidin-3-ylmethyl)-carbamic acid tert-butyl ester)
• 1049730-81-5(tert-butyl 3-[(methylamino)methyl]azetidine-1-carboxylate)
• 859027-41-1(Tert-butyl 3-[(dimethylamino)methyl]azetidine-1-carboxylate)
• 1041026-70-3(tert-Butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)